- Home
- MAX vs CRGX Comparison
MAX vs CRGX Comparison
Compare MAX & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- CRGX
- Stock Information
- Founded
- MAX 2014
- CRGX 2021
- Country
- MAX United States
- CRGX United States
- Employees
- MAX N/A
- CRGX N/A
- Industry
- MAX Industrial Machinery/Components
- CRGX
- Sector
- MAX Industrials
- CRGX
- Exchange
- MAX Nasdaq
- CRGX Nasdaq
- Market Cap
- MAX 613.7M
- CRGX 621.4M
- IPO Year
- MAX 2020
- CRGX 2023
- Fundamental
- Price
- MAX $11.24
- CRGX $12.86
- Analyst Decision
- MAX Buy
- CRGX Strong Buy
- Analyst Count
- MAX 8
- CRGX 6
- Target Price
- MAX $22.00
- CRGX $31.80
- AVG Volume (30 Days)
- MAX 460.9K
- CRGX 279.0K
- Earning Date
- MAX 02-18-2025
- CRGX 11-12-2024
- Dividend Yield
- MAX N/A
- CRGX N/A
- EPS Growth
- MAX N/A
- CRGX N/A
- EPS
- MAX 0.19
- CRGX N/A
- Revenue
- MAX $681,230,000.00
- CRGX N/A
- Revenue This Year
- MAX $124.41
- CRGX N/A
- Revenue Next Year
- MAX $31.11
- CRGX N/A
- P/E Ratio
- MAX $59.54
- CRGX N/A
- Revenue Growth
- MAX 72.47
- CRGX N/A
- 52 Week Low
- MAX $10.21
- CRGX $10.91
- 52 Week High
- MAX $25.78
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- MAX 46.70
- CRGX 42.73
- Support Level
- MAX $11.02
- CRGX $10.91
- Resistance Level
- MAX $11.45
- CRGX $15.75
- Average True Range (ATR)
- MAX 0.45
- CRGX 1.16
- MACD
- MAX 0.08
- CRGX -0.03
- Stochastic Oscillator
- MAX 59.63
- CRGX 39.63
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.